'General Electrical Medical Systems\r'

'Q1: What is the underlying logic behind the globose product company idea? worldwide harvest-time Company (GPC) philosophy is mainly aiming at producing products that fitting orbicular grocerys with lowest address and highest profit. This philosophy has mechanisms that leave been applied to opposite strains of product lifecycle: Manufacturing phase: In manufacturing phase, cutting costs was achieved by moving manufacturing activities and at last design and engineering activities from high-cost countries to low-priced countries.\r\nR& vitamin A;D phase: R& adenine;D is a very important phase in product development, it is essential to develop new products that dissolve compete in the global market and considers different customers’ needs. Having high skilled workers in developing countries, where fight has relatively lower costs, has enabled the movement of R& antiophthalmic factor;D from high-cost countries to low-cost countries, however R&D programs, objectiv es, and strategies were still managed by headquarter and the corporate global senior management.\r\nMarketing & Sales phase: On contrary to R&D and Manufacturing, marketing & sales have to be localized operations according to each parting and country. Accordingly, GEMS has established many offices around the world for sales and marketing management to get c pretermitr to the customer. Q2: Should the Global Product Company philosophy be neutered to suit the needs of medical diagnostic market in mainland China? China already has the threesome largest market for medical diagnostic after the States and Japan and it is already the fastest growing, it has the biggest market or low-ended products which has about 20% of the worldwide application revenues. Accordingly, in some manner the tenets of the GPC policies should change to increase the market shargon in the low-end products; GEMS should adopt the new â€Å"In China for China” insurance policy and bring the plants in already low-cost countries to China. According to Chinese culture and rules, domestic turnout ordain bring greater demand and will also bring a slight cost saving that could enable GEMS low-end products to compete with Siemens products that are already being manufactured in China.\r\ndropping the price with 10% can increase the sales with 50%. Although the â€Å"In China for China” policy might cause duplication in bag, the newly expected market share in the Chinese market can absorb this duplication of infrastructure and production. Q3: Should GEMS be pursuing genomics and health care IT opportunities sharp in addition, or instead of the China hazard? China opportunity is a cash scare for the time being, it represents the biggest opportunity in the low-ended products.\r\nOn the other hand, genomics and health care IT opportunities are the future of the industry they are star products. If GEMS did not look for opportunities and investments in genomics and hea lth care IT, then it will lose its market share in the high and medium-ended products which twain represents about 80% of the industry market. Accordingly, I cope with that GEMS should pursue genomics and health care IT opportunities aggressively in addition to the China opportunity.\r\n'